北陸藥業(300016.SZ):未來產品管線將以化學仿製藥和中成藥並重
格隆匯1月5日丨北陸藥業(300016.SZ)近期在接待機構投資者調研時表示,公司以“中國醫藥製造百強企業”為中長期發展目標,未來產品管線將以化學仿製藥和中成藥並重,圍繞公司重點佈局的心血管、消化、精神神經、內分泌等領域,積極拓展產品管線,打造豐富的產品矩陣。
中成藥是公司未來幾年重點佈局的領域,公司着力打造“抗焦慮第一品牌”品牌系列,計劃通過持續提升九味鎮心顆粒的市場份額來鞏固和擴大品牌影響力,並且圍繞該產品開發了系列保健品;同時,公司立足於中成藥板塊,正積極推進投資併購及BD 等多項工作,努力擴大公司在中成藥領域的佈局和投入,加速產品研發、市場推廣和品牌建設等方面的進程。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.